BUREAU-VERITAS
4.9.2024 08:01:32 CEST | Business Wire | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services, today announced the acquisition of ArcVera Renewables, a specialized provider in finance-grade consulting and technical services for wind, solar, and battery storage projects worldwide. This acquisition is aligned with Bureau Veritas LEAP | 28 strategy to create a new stronghold in the fast-growing sector of renewables.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903622866/en/
Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire)
Bureau Veritas contributes to the energy transition by providing the power sector customers end-to-end solutions to meet the immediate and future challenges of developing and operating renewable assets. This acquisition will expand Bureau Veritas’s capabilities, primarily in North America, to support landowners, developers and owners, and investors in delivering their wind and solar farm projects.
ArcVera Renewables provides customers with advanced technical site and resources assessments, and consultancy during the development and operations stages of utility-scale renewables projects. The company’s engineers, technical and subject matter experts support clients with risk reduction and ensure optimal asset performance. Since its inception, ArcVera Renewables has supported 9GW of solar projects in North and South America and has evaluated projects now representing 93,000 MW of wind capacity in the United States. ArcVera Renewables delivered revenues of €6.5 million in 2023 and is headquartered in Golden, Colorado.
“The acquisition of ArcVera Renewables supports our LEAP | 28 strategy, aimed at expanding our services and strengthening our position as a leader in the renewables and power generation sector,” said Hinda Gharbi, Chief Executive Officer of Bureau Veritas. “ArcVera Renewables has built a reputation for excellence in due diligence and operational verification on renewable projects. Their expertise will be a valuable addition to Bureau Veritas’s portfolio of capabilities for the energy transition services. I warmly welcome all new colleagues from ArcVera Renewables to Bureau Veritas.”
“We saw how the broad and deep technical prowess of Bureau Veritas would be a powerful catalyst for ArcVera Renewables” added Greg Poulos, CEO of ArcVera Renewables. “Since inception, our goal has been to accelerate the clean transformation of the world’s energy sector by delivering trustworthy, valuable, detailed, and independent technical analysis for the success of our clients. Joining Bureau Veritas is a leap forward in achieving this goal and is likewise transformational for the ArcVera team and its growing global renewable energy client-base.”
***
About Bureau Veritas
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress.
With a vision to be the preferred partner for its customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on LinkedIn.
About ArcVera Renewables
ArcVera Renewables provides finance-grade consulting and technical services for wind, solar and storage projects worldwide. For the last four decades, ArcVera Renewables has been dedicated to delivering next-generation innovation in renewable energy to meet the needs of landowners, project developers, investors, project owners and operators globally. ArcVera Renewables provides technically sound and accuracy-driven technical services, including prospecting and resource assessment, independent technical and financial engineering, as well as plant optimization, operations and repowering. Subsidiary offices are located in India, Brazil, and South Africa, serving all continents.
For more information, visit www.arcvera.com, and follow us on LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903622866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom